Repositioning Candidate Details
| Candidate ID: | R0868 |
| Source ID: | DB05772 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Rabeximod |
| Synonyms: | -- |
| Molecular Formula: | C22H24ClN5O |
| SMILES: | CN(C)CCNC(=O)CN1C2=CC=C(Cl)C=C2C2=C1N=C1C=C(C)C(C)=CC1=N2 |
| Structure: |
|
| DrugBank Description: | Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries. |
| CAS Number: | 872178-65-9 |
| Molecular Weight: | 409.92 |
| DrugBank Indication: | Investigated for use/treatment in rheumatoid arthritis. |
| DrugBank Pharmacology: | Rob 803 is an immunomodulator. |
| DrugBank MoA: | -- |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |